Dystonia is a disabling symptom affecting both patients with idiopathic Parkinson's disease (PD) and atypical parkinsonism (AP). Botulinum toxinum (BoNT), by blocking muscle contraction, is a possible treatment for focal dystonia. The benefit of BoNT treatment has been proven in some focal dystonia associated with PD or AP. The investigators aim to give an overview of the efficacy of BoNT in a variety of focal dystonia in a large cohort of parkinsonian patients.
Study Type
OBSERVATIONAL
Enrollment
63
Avicenne Hospital
Bobigny, Seine-Saint-Denis, France
Comparison of the patient reported efficacy of botulinum toxin treatment between PD and AP patients
Evaluation by the patient of the efficacy of the former injection on an improvement scale ranging from 0 to 100% (minimum value : 0, maximum value : 100, higher scores mean a better outcome) systematically made in routine care during follow up appointment
Time frame: Up to twelve months
Comparison of the patient reported duration of improvement after treatment by botulinum toxin between PD and AP patients
Evaluation by the patient of the duration of the period during which symptoms were improved (in weeks) systematically made in routine care during follow up appointment
Time frame: Up to twelve months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.